Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 93

1.

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

Fisher TS, Hooper AT, Lucas J, Clark TH, Rohner AK, Peano B, Elliott MW, Tsaparikos K, Wang H, Golas J, Gavriil M, Haddish-Berhane N, Tchistiakova L, Gerber HP, Root AR, May C.

Cancer Immunol Immunother. 2018 Feb;67(2):247-259. doi: 10.1007/s00262-017-2081-0. Epub 2017 Oct 24.

PMID:
29067496
2.

Caveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1).

Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, Tylaska L, King L, Zhou D, Dushin R, Myers JS, Rosfjord E, Lucas J, Gerber HP, Loganzo F.

Mol Cancer Ther. 2018 Jan;17(1):243-253. doi: 10.1158/1535-7163.MCT-17-0403. Epub 2017 Oct 20.

3.

Detecting expression of 5T4 in CTCs and tumor samples from NSCLC patients.

Pirie-Shepherd SR, Painter C, Whalen P, Vizcarra P, Roy M, Qian J, Franks T, Coskran T, Golas J, Deng S, Zhong W, Tucker E, Marrinucci D, Gerber HP, Powell EL.

PLoS One. 2017 Jul 20;12(7):e0179561. doi: 10.1371/journal.pone.0179561. eCollection 2017.

4.

Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug Conjugates.

Tumey LN, Li F, Rago B, Han X, Loganzo F, Musto S, Graziani EI, Puthenveetil S, Casavant J, Marquette K, Clark T, Bikker J, Bennett EM, Barletta F, Piche-Nicholas N, Tam A, O'Donnell CJ, Gerber HP, Tchistiakova L.

AAPS J. 2017 Jul;19(4):1123-1135. doi: 10.1208/s12248-017-0083-7. Epub 2017 Apr 24.

PMID:
28439809
5.

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions.

Damelin M, Bankovich A, Bernstein J, Lucas J, Chen L, Williams S, Park A, Aguilar J, Ernstoff E, Charati M, Dushin R, Aujay M, Lee C, Ramoth H, Milton M, Hampl J, Lazetic S, Pulito V, Rosfjord E, Sun Y, King L, Barletta F, Betts A, Guffroy M, Falahatpisheh H, O'Donnell CJ, Stull R, Pysz M, Escarpe P, Liu D, Foord O, Gerber HP, Sapra P, Dylla SJ.

Sci Transl Med. 2017 Jan 11;9(372). pii: eaag2611. doi: 10.1126/scitranslmed.aag2611.

PMID:
28077676
6.

Next-Generation Antibody-Drug Conjugates (ADCs) for Cancer Therapy.

Junutula JR, Gerber HP.

ACS Med Chem Lett. 2016 Nov 10;7(11):972-973. eCollection 2016 Nov 10. No abstract available.

7.

Mechanisms of Resistance to Antibody-Drug Conjugates.

Loganzo F, Sung M, Gerber HP.

Mol Cancer Ther. 2016 Dec;15(12):2825-2834. Epub 2016 Oct 25. Review.

8.

Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring.

Guffroy M, Falahatpisheh H, Biddle K, Kreeger J, Obert L, Walters K, Goldstein R, Boucher G, Coskran T, Reagan W, Sullivan D, Huang C, Sokolowski S, Giovanelli R, Gerber HP, Finkelstein M, Khan N.

Clin Cancer Res. 2017 Apr 1;23(7):1760-1770. doi: 10.1158/1078-0432.CCR-16-0939. Epub 2016 Sep 28.

9.

Natural Product Splicing Inhibitors: A New Class of Antibody-Drug Conjugate (ADC) Payloads.

Puthenveetil S, Loganzo F, He H, Dirico K, Green M, Teske J, Musto S, Clark T, Rago B, Koehn F, Veneziale R, Falahaptisheh H, Han X, Barletta F, Lucas J, Subramanyam C, O'Donnell CJ, Tumey LN, Sapra P, Gerber HP, Ma D, Graziani EI.

Bioconjug Chem. 2016 Aug 17;27(8):1880-8. doi: 10.1021/acs.bioconjchem.6b00291. Epub 2016 Jul 28.

PMID:
27412791
10.

Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?

Gerber HP, Sapra P, Loganzo F, May C.

Biochem Pharmacol. 2016 Feb 15;102:1-6. doi: 10.1016/j.bcp.2015.12.008. Epub 2015 Dec 11. Review.

PMID:
26686577
11.

Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions.

Damelin M, Bankovich A, Park A, Aguilar J, Anderson W, Santaguida M, Aujay M, Fong S, Khandke K, Pulito V, Ernstoff E, Escarpe P, Bernstein J, Pysz M, Zhong W, Upeslacis E, Lucas J, Lucas J, Nichols T, Loving K, Foord O, Hampl J, Stull R, Barletta F, Falahatpisheh H, Sapra P, Gerber HP, Dylla SJ.

Clin Cancer Res. 2015 Sep 15;21(18):4165-73. doi: 10.1158/1078-0432.CCR-15-0695. Epub 2015 May 26.

12.

Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments.

Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E, Wang F, Diesl V, Follettie MT, Musto S, Lam MH, Hu W, Charati MB, Khandke K, Kim KS, Cinque M, Lucas J, Graziani E, Maderna A, O'Donnell CJ, Arndt KT, Gerber HP.

Mol Cancer Ther. 2015 Apr;14(4):952-63. doi: 10.1158/1535-7163.MCT-14-0862. Epub 2015 Feb 2.

13.

Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.

Shor B, Gerber HP, Sapra P.

Mol Immunol. 2015 Oct;67(2 Pt A):107-16. doi: 10.1016/j.molimm.2014.09.014. Epub 2014 Oct 7. Review.

PMID:
25304309
14.

Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology.

Rosfjord E, Lucas J, Li G, Gerber HP.

Biochem Pharmacol. 2014 Sep 15;91(2):135-43. doi: 10.1016/j.bcp.2014.06.008. Epub 2014 Jun 17. Review.

PMID:
24950467
15.

A general approach to site-specific antibody drug conjugates.

Tian F, Lu Y, Manibusan A, Sellers A, Tran H, Sun Y, Phuong T, Barnett R, Hehli B, Song F, DeGuzman MJ, Ensari S, Pinkstaff JK, Sullivan LM, Biroc SL, Cho H, Schultz PG, DiJoseph J, Dougher M, Ma D, Dushin R, Leal M, Tchistiakova L, Feyfant E, Gerber HP, Sapra P.

Proc Natl Acad Sci U S A. 2014 Feb 4;111(5):1766-71. doi: 10.1073/pnas.1321237111. Epub 2014 Jan 17.

16.

On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach.

Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM.

J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):557-71. doi: 10.1007/s10928-013-9329-x. Epub 2013 Aug 10.

PMID:
23933716
17.

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.

Gerber HP, Koehn FE, Abraham RT.

Nat Prod Rep. 2013 May;30(5):625-39. doi: 10.1039/c3np20113a. Review.

PMID:
23525375
18.

8(th) Annual European Antibody Congress 2012: November 27-28, 2012, Geneva, Switzerland.

Beck A, Carter PJ, Gerber HP, Lugovskoy AA, Wurch T, Junutula JR, Kontermann RE, Mabry R.

MAbs. 2013 May-Jun;5(3):339-57. doi: 10.4161/mabs.24105. Epub 2013 Mar 14.

19.

Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells.

Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, Dougher M, Narayanan B, Giannakou A, Khandke K, Dushin R, Ernstoff E, Lucas J, Leal M, Hu G, O'Donnell CJ, Tchistiakova L, Abraham RT, Gerber HP.

Mol Cancer Ther. 2013 Jan;12(1):38-47. doi: 10.1158/1535-7163.MCT-12-0603. Epub 2012 Dec 5.

20.

Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier function.

Jin J, Sison K, Li C, Tian R, Wnuk M, Sung HK, Jeansson M, Zhang C, Tucholska M, Jones N, Kerjaschki D, Shibuya M, Fantus IG, Nagy A, Gerber HP, Ferrara N, Pawson T, Quaggin SE.

Cell. 2012 Oct 12;151(2):384-99. doi: 10.1016/j.cell.2012.08.037.

Supplemental Content

Loading ...
Support Center